Evidence map›Paper›PMID 41448855›Full record

ArticleCancer research communications2025

Periostin Promotes Sarcoma Growth by Promoting Tumor-Associated Macrophage Migration and Differentiation.

Jin-Fen Xiao, Kristin Ishaya, Emily Y Ko, Annaliese Fowler, Marina T Broz, Jlenia Guarnerio

Abstract read
In one paragraph

Article in Cancer research communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jin-Fen XiaoDepartment of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, California.ORCID 0000-0003-3366-5984
Kristin IshayaDepartment of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, California.ORCID 0009-0008-5750-9824
Emily Y KoDepartment of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, California.ORCID 0000-0002-4893-3227
Annaliese FowlerDepartment of Genetics, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0009-0002-8510-2219
Marina T BrozDepartment of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California.ORCID 0000-0003-2875-9273
Jlenia GuarnerioDepartment of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, California.ORCID 0000-0001-7576-7095

Funding

Comparative modeling of sarcoma microenvironments for the discovery of biomarkers and tumor vulnerabilitiesR01CA258265 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI GUARNERIO, JLENIA · 2021 to 2025
$2.3M
Glut1+ cancer associated fibroblasts enforce a metabolic barrier to tumor T cell infiltrationF31CA284888 · NCI · CEDARS-SINAI MEDICAL CENTER · PI BROZ, MARINA T · 2023 to 2023
$41k
National Cancer Institute (NCI) CA258265National Cancer Institute (NCI) F31CA284888NCI NIH HHS F31 CA284888NCI NIH HHS R01 CA258265U.S. Department of Defense (DOD) HT9425-23-1-0775
6 · The paper itself

Abstract

Soft-tissue sarcomas (STS) are characterized by abundant extracellular matrix (ECM) deposition, yet the functional contribution of specific ECM components remains poorly understood. In this study, we identify periostin (POSTN), a matricellular protein, as a regulator of sarcoma progression and the tumor immune microenvironment. Analysis of human sarcoma datasets revealed that high POSTN expression correlates with poor prognosis and elevated expression of ECM-related and myeloid cell-associated genes. In murine genetic models of sarcoma, tumors expressing high levels of Postn displayed enhanced expression of ECM genes and monocyte-recruiting cytokines. Functional silencing of Postnin vivo reduced tumor growth without altering tumor cell proliferation or intrinsic signaling pathways, suggesting a noncell-autonomous mechanism. Instead, Postn-deficient tumors showed increased infiltration of CD4+ and CD8+ T cells and reduced proportions of immunosuppressive myeloid cells, including tumor-associated macrophages (TAM). Single-cell RNA sequencing revealed that Postn silencing reprograms the myeloid compartment, increasing IFN-responsive and proinflammatory subsets. Mechanistically, recombinant POSTN promoted monocyte migration and maturation into macrophages in vitro, supporting its role as a chemoattractant and differentiation cue. Therapeutic neutralization of POSTN partially recapitulated the immunologic remodeling but was insufficient to reduce tumor burden as monotherapy. SIGNIFICANCE: Our findings position POSTN as a key stromal regulator in STS, linking tumor-derived ECM components to immune evasion via myeloid cell recruitment and education. These results open avenues for targeting POSTN as an adjuvant strategy to enhance the efficacy of immunotherapies and overcome the immune-excluded phenotype of sarcoma.

Indexed as

Cell Adhesion MoleculesSarcomaTumor-Associated MacrophagesAnimalsCell DifferentiationCell Line, TumorCell MovementCell ProliferationGene Expression Regulation, NeoplasticHumansMicePeriostinTumor MicroenvironmentCell Adhesion MoleculesPeriostinPOSTN protein, humanPostn protein, mouse

Identifiers

PMID41448855
PMCPMC12740715

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.